- Elli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk. Barron’s
- Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease Eli Lilly and Company
- Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity CNBC
- Eli Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment statnews.com
- Lilly stock falls as Mounjaro fails to show superiority over Trulicity Yahoo Finance
Source link
